Cardinal Health, Inc.

New York Stock Exchange
Back to all articles
Bullish +55

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

AI-generated analysis

📈 Jim Cramer identifies Cardinal Health (CAH) as an 'absolute favorite' due to its transition into specialized healthcare services and specialty pharmaceuticals.

💰 Fiscal Q4 revenue rose 6% to $63.7 billion, though it missed estimates, partially offset by a $0.31 per share tariff refund benefit.

🚀 Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, targeting a range of $12.40 to $12.60.

🏥 The 'Other' segment, including precision health and at-home solutions, is expected to deliver 11% to 13% revenue growth in fiscal 2027.

🤝 Cardinal Health agreed to acquire AdaptHealth's diabetes business and Strive Medical for approximately $360 million to expand at-home operations.

⚠️ The stock has rerated close to record highs, creating a risk of a sharper valuation reset if specialty growth slows or margins fall short.

🏪 Customer concentration remains a vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.

💸 Projected fiscal 2027 adjusted free cash flow of $3.5 billion to $4 billion is below the roughly $5 billion generated in fiscal 2026.

📉 Hedge fund ownership decreased slightly, with 63 funds holding CAH in Q2 compared to 66 in Q1.

📊 The company trades at a forward P/E of 19.01, requiring management to deliver on growth targets to justify the current valuation.

Bullish Signals
  • Jim Cramer calls Cardinal Health an 'absolute favorite' due to its successful pivot from commoditized distribution to specialized healthcare services.
  • The company is running circles around competitors like McKesson and Cencora by converting pharmaceutical volume into earnings effectively.
  • Fiscal Q4 revenue grew 6% to $63.7 billion, demonstrating resilience despite lower branded-drug prices affecting reported sales.
  • Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, projecting a range of $12.40 to $12.60.
  • The 'Other' segment is expected to produce 11% to 13% revenue growth and 15% to 18% profit growth in fiscal 2027.
  • Cardinal Health agreed to acquire AdaptHealth's diabetes business and Strive Medical for approximately $360 million to expand its at-home medical-supply operations.
Risk Factors
  • The stock has rerated close to its record high, creating a risk of a sharper valuation reset if specialty growth slows or margins fall short.
  • Customer concentration is a significant vulnerability, with CVS Health accounting for 28% of fiscal 2026 revenue and the top five customers representing 43%.
  • Projected fiscal 2027 adjusted free cash flow of $3.5 billion to $4 billion is below the roughly $5 billion generated in fiscal 2026.
  • Lower branded-drug prices, including those affected by Medicare negotiations, can reduce reported sales without a proportional decline in distributor fees.
  • The shift toward generics can have a similar effect because lower-priced drugs generate less revenue but can support attractive margins and high volumes.
Full Analysis
Jim Cramer highlighted Cardinal Health (CAH) as an 'absolute favorite' on Mad Money, citing its strategic shift from a commoditized distributor to a specialized player with growing exposure to higher-margin healthcare services and specialty pharmaceuticals. The company has outperformed peers like McKesson and Cencora by converting volume into earnings despite headwinds in branded-drug pricing and Medicare negotiations. Cardinal Health reported fiscal fourth-quarter revenue of $63.7 billion, a 6% increase that missed estimates but was offset by a $0.31 per share tariff refund benefit. Management forecasts fiscal 2027 non-GAAP EPS growth of 13% to 15%, targeting $12.40 to $12.60, while expecting adjusted free cash flow between $3.5 billion and $4 billion. The company is expanding its 'Other' segment, which includes precision health solutions and at-home services, with projected revenue growth of 11% to 13%. The stock faces risks related to execution and valuation after a substantial rerate near record highs. Key vulnerabilities include customer concentration, where CVS Health accounts for 28% of fiscal 2026 revenue, and the potential for margins to fall short if specialty growth slows or drug-pricing pressures intensify. Additionally, projected fiscal 2027 free cash flow is lower than the roughly $5 billion generated in fiscal 2026, raising questions about capital generation capabilities. Institutional ownership data shows 63 hedge funds held CAH in the second quarter, down slightly from 66 in the first. Cramer argues that despite these risks and the high forward P/E of 19.01, the company offers a credible case for its valuation given the targeted earnings growth, positioning it as a potential winner in an environment concerned with oil prices and interest rates.